Body mass index and blood pressure in bipolar patients: Target cardiometabolic markers for clinical practice

Alfredo B. Cuellar-Barboza, Alejandra Cabello-Arreola, Stacey J. Winham, Colin Colby, Francisco Romo-Nava, Nicolas A. Nunez, Robert J. Morgan, Ruchi Gupta, Joshua T. Bublitz, Miguel L. Prieto, Elena A. De Filippis, Francisco Lopez-Jimenez, Susan L. McElroy, Joanna M. Biernacka, Mark A. Frye, Marin Veldic*

*Autor correspondiente de este trabajo

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

1 Cita (Scopus)

Resumen

Objective: To evaluate the association between cardiometabolic markers and bipolar disorder (BD), examining the impact of sex and cardiometabolic medication use, from a large case-control biorepository of more than 1300 participants. Patients and Methods: Recruited from July 2009 through September 2017, cardiometabolic markers were harvested from electronic health records (EHR) of participants (n=661) from the Mayo Clinic Individualized Medicine Biobank for Bipolar Disorder and Mayo Clinic Biobank age-sex-matched controls (n=706). Markers were compared between cases and controls using logistic regression, stratified by sex, adjusting for cardiometabolic medications and current smoking status. We studied the effect of psychotropics in case-only analyses. Results: The mean age of the sample was 52.5 ± 11.6 years and 55% were female. BD patients had higher rates of smoking, but lower utilization of lipid-lowering medication compared with controls. After adjustment, BD was associated with obesity [Odds ratio (CI) 1.62 (1.22-2.15)], elevated systolic blood pressure (SBP) [2.18 (1.55-3.06)] and elevated triglycerides [1.58 (1.13-2.2)]. When stratified by sex, obesity [1.8 (1.23-2.66)] and systolic blood pressure [2.32 (1.46-3.7)] were associated with BD females compared to female controls; however, only systolic blood pressure [2.04 (1.23-3.42)] was associated with male bipolars compared to male controls. Psychotropics were marginally associated with mean BMI, abnormal triglycerides, and HbA1c. Limitations: EHR cross-sectional data Conclusion: To our knowledge, this is the largest case controlled study to date to explore the association between cardiometabolic markers and bipolar disorder adjusting for utilization of cardiometabolic medication. Identification of significant, non-laboratory based cardiometabolic markers that are associated with increased risk of major cardiovascular adverse events in patients with bipolar disorder, underscores, both the utility and importance of risk monitoring that can be easily done in community mental health centers.

Idioma originalInglés
Páginas (desde-hasta)637-643
Número de páginas7
PublicaciónJournal of Affective Disorders
Volumen282
DOI
EstadoPublicada - 1 mar 2021
Publicado de forma externa

Huella

Profundice en los temas de investigación de 'Body mass index and blood pressure in bipolar patients: Target cardiometabolic markers for clinical practice'. En conjunto forman una huella única.

Citar esto